Does the media prefer IRON or ARWR?

In the previous week, Disc Medicine had 10 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 20 mentions for Disc Medicine and 10 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.62 beat Disc Medicine's score of 0.80 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer RGC or IRON?

Disc Medicine has a consensus target price of $105.30, indicating a potential upside of 54.88%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Disc Medicine is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Disc Medicine 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75

Which has better valuation and earnings, RGC or IRON?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is RGC or IRON more profitable?

Regencell Bioscience's return on equity of 0.00% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Disc Medicine N/A -36.94% -33.88%

Does the media prefer RGC or IRON?

In the previous week, Regencell Bioscience had 1 more articles in the media than Disc Medicine. MarketBeat recorded 21 mentions for Regencell Bioscience and 20 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.80 beat Regencell Bioscience's score of 0.14 indicating that Disc Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 1 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Disc Medicine 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, IRON or NUVL?

Nuvalent is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.62 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is IRON or NUVL more profitable?

Disc Medicine's return on equity of -36.94% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -36.94% -33.88% Nuvalent N/A -40.11% -35.43%

Does the media favor IRON or NUVL?

In the previous week, Nuvalent had 40 more articles in the media than Disc Medicine. MarketBeat recorded 60 mentions for Nuvalent and 20 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.80 beat Nuvalent's score of 0.18 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 19 Very Positive mention(s) 8 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to KRYS or IRON?

In the previous week, Disc Medicine had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 20 mentions for Disc Medicine and 9 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.50 beat Disc Medicine's score of 0.80 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Disc Medicine 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRON or CYTK?

In the previous week, Disc Medicine had 4 more articles in the media than Cytokinetics. MarketBeat recorded 20 mentions for Disc Medicine and 16 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 1.00 beat Disc Medicine's score of 0.80 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 8 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Disc Medicine (IRON) Competitors

$67.99 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$67.98 0.00 (-0.01%)

As of 06/12/2026 04:16 PM Eastern

Compare

IRON vs. ARWR, RGC, NUVL, KRYS, and CYTK

Should you buy Disc Medicine stock or one of its competitors? MarketBeat compares Disc Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Disc Medicine include Arrowhead Pharmaceuticals (ARWR), Regencell Bioscience (RGC), Nuvalent (NUVL), Krystal Biotech (KRYS), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry.

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Disc Medicine (NASDAQ:IRON) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Disc Medicine has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market.

Disc Medicine currently has a consensus price target of $105.30, suggesting a potential upside of 54.88%. Arrowhead Pharmaceuticals has a consensus price target of $87.80, suggesting a potential upside of 17.82%. Given Disc Medicine's higher possible upside, research analysts clearly believe Disc Medicine is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arrowhead Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Arrowhead Pharmaceuticals has higher revenue and earnings than Disc Medicine. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Arrowhead Pharmaceuticals	$829.45M	12.66	-$1.63M	-$2.15	N/A

Disc Medicine has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Disc Medicine's return on equity of -36.94% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

In the previous week, Disc Medicine had 10 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 20 mentions for Disc Medicine and 10 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 1.62 beat Disc Medicine's score of 0.80 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Disc Medicine beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Disc Medicine compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Disc Medicine (NASDAQ:IRON) are both mid-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Regencell Bioscience has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Regencell Bioscience's return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Disc Medicine	N/A	-36.94%	-33.88%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

In the previous week, Regencell Bioscience had 1 more articles in the media than Disc Medicine. MarketBeat recorded 21 mentions for Regencell Bioscience and 20 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.80 beat Regencell Bioscience's score of 0.14 indicating that Disc Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	1 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Disc Medicine	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Disc Medicine has a consensus target price of $105.30, indicating a potential upside of 54.88%. Given Disc Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Disc Medicine is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Disc Medicine beats Regencell Bioscience on 6 of the 11 factors compared between the two stocks.

How does Disc Medicine compare to Nuvalent?

Disc Medicine (NASDAQ:IRON) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

In the previous week, Nuvalent had 40 more articles in the media than Disc Medicine. MarketBeat recorded 60 mentions for Nuvalent and 20 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.80 beat Nuvalent's score of 0.18 indicating that Disc Medicine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	19 Very Positive mention(s)	8 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Disc Medicine presently has a consensus target price of $105.30, suggesting a potential upside of 54.88%. Nuvalent has a consensus target price of $131.15, suggesting a potential upside of 6.41%. Given Disc Medicine's stronger consensus rating and higher possible upside, equities analysts clearly believe Disc Medicine is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Nuvalent	1 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Nuvalent is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Disc Medicine has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

Disc Medicine's return on equity of -36.94% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Nuvalent	N/A	-40.11%	-35.43%

Summary

Disc Medicine beats Nuvalent on 8 of the 13 factors compared between the two stocks.

How does Disc Medicine compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Disc Medicine (NASDAQ:IRON) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Krystal Biotech has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.09	$204.83M	$7.48	42.51
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 3.8% of Disc Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Krystal Biotech has a net margin of 53.92% compared to Disc Medicine's net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Disc Medicine	N/A	-36.94%	-33.88%

Krystal Biotech presently has a consensus target price of $324.11, suggesting a potential upside of 1.93%. Disc Medicine has a consensus target price of $105.30, suggesting a potential upside of 54.88%. Given Disc Medicine's higher possible upside, analysts clearly believe Disc Medicine is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Disc Medicine had 11 more articles in the media than Krystal Biotech. MarketBeat recorded 20 mentions for Disc Medicine and 9 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.50 beat Disc Medicine's score of 0.80 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Disc Medicine	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Krystal Biotech beats Disc Medicine on 11 of the 14 factors compared between the two stocks.

How does Disc Medicine compare to Cytokinetics?

Disc Medicine (NASDAQ:IRON) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Disc Medicine has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Disc Medicine had 4 more articles in the media than Cytokinetics. MarketBeat recorded 20 mentions for Disc Medicine and 16 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 1.00 beat Disc Medicine's score of 0.80 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	8 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Disc Medicine presently has a consensus target price of $105.30, suggesting a potential upside of 54.88%. Cytokinetics has a consensus target price of $99.30, suggesting a potential upside of 41.55%. Given Disc Medicine's higher probable upside, equities research analysts plainly believe Disc Medicine is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Disc Medicine has higher earnings, but lower revenue than Cytokinetics. Disc Medicine is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Cytokinetics	$88.04M	99.15	-$784.96M	-$6.84	N/A

Disc Medicine has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market.

83.7% of Disc Medicine shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Disc Medicine beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

Get Disc Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRON vs. The Competition

Export

Metric	Disc Medicine	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.59B	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-10.27	19.82	24.21	24.42
Price / Sales	N/A	305.69	512.04	109.94
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	3.48	8.32	10.66	6.83
Net Income	-$212.18M	$23.94M	$3.57B	$337.67M
7 Day Performance	3.33%	1.84%	0.58%	1.17%
1 Month Performance	1.69%	-0.04%	1.54%	3.16%
1 Year Performance	26.59%	44.82%	25.40%	30.58%

Disc Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRON Disc Medicine	2.1741 of 5 stars	$67.99 flat	$105.30 +54.9%	+26.6%	$2.59B	N/A	N/A	30	News Coverage Analyst Forecast
ARWR Arrowhead Pharmaceuticals	2.78 of 5 stars	$73.33 -0.7%	$87.80 +19.7%	+373.4%	$10.33B	$622.01M	N/A	400	News Coverage Positive News
RGC Regencell Bioscience	0.2966 of 5 stars	$20.31 -5.0%	N/A	N/A	$10.04B	N/A	N/A	10	Trending News Gap Up
NUVL Nuvalent	1.8102 of 5 stars	$123.25 +39.3%	$134.60 +9.2%	+57.5%	$9.74B	N/A	N/A	40	Trending News High Trading Volume
KRYS Krystal Biotech	3.1841 of 5 stars	$309.75 +2.6%	$324.11 +4.6%	+132.0%	$9.13B	$389.13M	41.41	210	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRON) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Disc Medicine (IRON) Competitors

IRON vs. ARWR, RGC, NUVL, KRYS, and CYTK

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Summary

How does Disc Medicine compare to Regencell Bioscience?

Summary

How does Disc Medicine compare to Nuvalent?

Summary

How does Disc Medicine compare to Krystal Biotech?

Summary

How does Disc Medicine compare to Cytokinetics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Disc Medicine (IRON) Competitors

IRON vs. ARWR, RGC, NUVL, KRYS, and CYTK

How does Disc Medicine compare to Arrowhead Pharmaceuticals?

Which has more volatility and risk, IRON or ARWR?

Do analysts rate IRON or ARWR?

Do insiders & institutionals hold more shares of IRON or ARWR?

Which has stronger earnings and valuation, IRON or ARWR?

Is IRON or ARWR more profitable?

Does the media prefer IRON or ARWR?

Summary

How does Disc Medicine compare to Regencell Bioscience?

Do insiders and institutionals believe in RGC or IRON?

Which has more volatility and risk, RGC or IRON?

Is RGC or IRON more profitable?

Which has better valuation and earnings, RGC or IRON?

Does the media prefer RGC or IRON?

Do analysts prefer RGC or IRON?

Summary

How does Disc Medicine compare to Nuvalent?

Does the media favor IRON or NUVL?

Do analysts recommend IRON or NUVL?

Do institutionals and insiders hold more shares of IRON or NUVL?

Which has preferable valuation & earnings, IRON or NUVL?

Which has more volatility and risk, IRON or NUVL?

Is IRON or NUVL more profitable?

Summary

How does Disc Medicine compare to Krystal Biotech?

Which has stronger earnings and valuation, KRYS or IRON?

Which has more risk and volatility, KRYS or IRON?

Do institutionals and insiders have more ownership in KRYS or IRON?

Is KRYS or IRON more profitable?

Do analysts prefer KRYS or IRON?

Does the media refer more to KRYS or IRON?

Summary

How does Disc Medicine compare to Cytokinetics?

Is IRON or CYTK more profitable?

Does the media favor IRON or CYTK?

Do analysts rate IRON or CYTK?

Which has stronger valuation & earnings, IRON or CYTK?

Which has more risk & volatility, IRON or CYTK?

Do insiders & institutionals hold more shares of IRON or CYTK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRON vs. The Competition

Disc Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools